Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

December 12, 2025

Study Completion Date

June 12, 2026

Conditions
TB
Interventions
DRUG

[U-14C] WX-081

A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY

NCT06701110 - Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter